Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza a viruses

PLoS Pathogens

Volumn 6, Issue 8, 2010, Pages 97-98

  Kiso, Maki ^a   Shinya, Kyoko ^b   Shimojima, Masayuki ^a   Takano, Ryo ^a   Takahashi, Kei ^a   Katsura, Hiroaki ^a   Kakugawa, Satoshi ^a   Le, Mai Thi Quynh ^c   Yamashita, Makoto ^d   Furuta, Yousuke ^e   Ozawa, Makoto ^a,f   Kawaoka, Yoshihiro ^a,b,f,g  

^a UNIVERSITY OF TOKYO   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

^d DAIICHI SANKYO CO   (Japan)

^e TOYAMA CHEMICAL CO LTD   (Japan)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ANTIVIRUS AGENT; CS 8958; FAVIPIRAVIR; OSELTAMIVIR; R 125489; UNCLASSIFIED DRUG; ZANAMIVIR; SIALIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MALE; MOUSE; NONHUMAN; PANDEMIC; PATHOGENICITY; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; ANIMAL; ANTIVIRAL RESISTANCE; BAGG ALBINO MOUSE; DISEASE TRANSMISSION; DRUG EFFECT; FERRET; GENETICS; MUTATION; ORTHOMYXOVIRUS INFECTION;

ANIMALIA; INFLUENZA A VIRUS; MUS; MUSTELA; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; FERRETS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MALE; MICE; MICE, INBRED BALB C; MUTATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; PANDEMICS; VIRUS REPLICATION;

EID: 77958136671     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1001079     Document Type: Article

References (28)

1. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360: 2605-2615.
2. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025.
3. Munster VJ, de Wit E, van den Brand JM, Herfst S, Schrauwen EJ, et al. (2009) Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 325: 481-483.
4. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, et al. (2009) Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325: 484-487.
5. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, et al. (2009) Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 361: 1935-1944.
6. Centers for Disease Control and Prevention (2009) Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 58: 433-435.
7. Gubareva LV, Kaiser L, Hayden FG (2000) Influenza virus neuraminidase inhibitors. Lancet 355: 827-835.
8. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, et al. (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364: 759-765.
9. Zambon M, Hayden FG (2001) Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res 49: 147-156.
10. Ward P, Small I, Smith J, Suter P, Dutkowski R (2005) Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 55 Suppl 1: i5-i21.
11. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, et al. (2005) Avian flu: isolation of drug-resistant H5N1 virus. Nature 437: 1108.
12. Centers for Disease Control and Prevention (2009) Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 58: 893-896.
13. Leung TW, Tai AL, Cheng PK, Kong MS, Lim W (2009) Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. J Clin Virol 46: 298-299.
14. Le QM, Wertheim HF, Tran ND, van Doorn HR, Nguyen TH, et al. (2010) A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 362: 86-87.
15. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, et al. (2009) CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 53: 186-192.
16. Neumann G, Noda T, Kawaoka Y (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459: 931-939.
17. Ison MG, Mishin VP, Braciale TJ, Hayden FG, Gubareva LV (2006) Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J Infect Dis 193: 765-772.
18. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 70: 121-131.
19. Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 5: e9332.
20. Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, et al. (2008) Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 52: 3889-3897.
21. Govorkova EA, Fang HB, Tan M, Webster RG (2004) Neuraminidase inhibitor- rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 48: 4855-4863.
22. Morrison D, Roy S, Rayner C, Amer A, Howard D, et al. (2007) A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS ONE 2: e1305.
23. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O (2009) Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 15: 155-162.
24. Nicoll A, Ciancio B, Kramarz P (2008) Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation and potential implications. Euro Surveill 13.
25. Lackenby A, Thompson CI, Democratis J (2008) The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 21: 626-638.
26. Honda T, Kubo S, Masuda T, Arai M, Kobayashi Y, et al. (2009) Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O- methyl-Neu5Ac2en. Bioorg Med Chem Lett 19: 2938-2940.
27. Gubareva LV, Webster RG, Hayden FG (2001) Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Che-mother 45: 3403-3408.
28. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, et al. (2007) Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. Jama 297: 1435-1442.